🔗 Share this article

A shadow economy for unapproved slimming drugs is being driven by social media fitness personalities and sellers on communication apps, according to recent findings.

Investigational Drug Acquiring Traction Via Social Media

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its alleged weight-reducing properties. Followers are urged to contact these accounts directly for supplier links, while also receiving discount codes.

Active Trade on Messaging Platforms

Additionally, a flourishing trade exists on messaging services, where communities with thousands of participants share “before and after” photos, injection guides and claims of next-day UK delivery. Sellers promote the drug there before redirecting buyers to other platforms for purchases.

Learning About Retatrutide

This medication is an investigational injection developed by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – GLP-1, GIP and glucagon. Early trials indicate it could assist patients lose up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Healthcare Experts Express Concerns

Nevertheless, physicians and chemists have cautions that the sale of what is still an unlicensed medication in the United Kingdom is a cause for concern and could lead to individuals injecting products of unknown origin.

Several professionals said the popularity for the experimental drug could be connected to the rising cost of approved slimming treatments such as Mounjaro.

Regulatory Position and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some content creators try to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and distribution can still violate medicines, marketing, and customer laws, potentially leading to penalties, legal action or prison.

Service Reaction and Material Elimination

Based on the social media company, the service has taken down problematic content and banned associated keywords and query recommendations. The company said it was dedicated to maintaining the platform secure and allocating resources in enhancing enforcement strategies.

Online Marketplace Activities

Investigations also found groups with up to nine thousand members selling retatrutide using the platform's built-in discovery tool, which functions like a public directory. Entering “retatrutide” instantly brings up groups with thousands of users, filled with photos of weight loss, glowing testimonials and detailed guides for preparing or injecting at residence.

Within minutes of entering one group, a seller shared contact information, where most transactions take place. The seller sent an instruction manual and guaranteed delivery within two days. When asked whether the product was authentic, one seller said: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. None asked about weight, medical conditions or previous experience.

Item Details and Costs

Within these communities, posts display black plastic parcels with Royal Mail labels, claiming to include new batches. One message read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at residence with purified liquid, or pre-filled injectors typically priced at £160 for 20 milligrams. When questioned how long a pen should be used, vendors give conflicting answers varying between a few weeks to “depends on your body”.

Platform Oversight and Safety Measures

A representative for Telegram stated it actively moderated harmful content on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“Individuals are injecting substances they cannot confirm. Although the research behind this drug is valid, these digital products may not contain what they advertise,” said Jason Murphy, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service connected the increase in demand to current cost increases for authorized weight-loss drugs such as Mounjaro. “With costs increasing, patients are using social media. But counterfeit injections are highly dangerous. You cannot know what’s inside or whether the environment they were made in was clean,” she said.

Her staff has already encountered patients injured by personal administration from unconfirmed suppliers. “We recognize the disappointment, but buying from messaging apps or WhatsApp is gambling with your well-being,” stated the doctor. “These materials could be impure or improperly measured.”

Producer Position

A representative from Eli Lilly said the substance was in third stage clinical trials and had not been evaluated or approved by any government authority globally. “Consequently at this time no one can sell [it] for human use,” they said, noting that any item “falsely representing itself as a company investigational product not yet approved … may subject patients to possibly serious health risks”.